Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction
Sponsor: Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana
Summary
Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages. The most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment. The immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition. The objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction.
Official title: An Open Label, Randomised, Controlled Clinical Trial to Asses the Safety of Endobronchial Administration of Allogneic Mesenchymal Stromal Cells in Patients With Lung Trasplant Chronic Rejection: Endosclad Study.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2023-09-19
Completion Date
2026-03-31
Last Updated
2024-07-26
Healthy Volunteers
No
Interventions
Mesenchymal stem cells
Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
Locations (1)
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain